Marc I. Lorber

Marc Lorber has been Chief Medical Officer and Senior Vice President, Clinical Development, XenoLung, since August 2012.

Prior to joining Lung Biotechnology, he served in several drug development roles at Novartis, most recently as Vice President and Therapeutic Area Head, responsible for transplantation, nephrology and autoimmunity indications in the IHC Global Development Franchise. Prior to joining Novartis in 2007, Dr. Lorber was Chief of Organ Transplantation and Immunology at Yale University School of Medicine for nearly 21 years, where he was also Professor of Surgery and Pathology. He was an active researcher and busy clinical transplant surgeon; he has published extensively and delivered scientific addresses in his areas of expertise across the world. Dr. Lorber is Past President of the American Society of Transplant Surgeons, a past member of the Board of Directors and Secretary of the United Network for Organ Sharing, and he served on the Advisory Committee for Organ Transplantation, U.S. Department of Health and Human Services.